Group items tagged

New immune system-boosting cancer drugs have in clinical trials saved the lives of many people with seemingly untreatable melanoma or lung cancer, but the drugs seem useless against colon cancer. One exception-a man with colon cancer whose metastatic tumors vanished for several years after he was treated in 2007-piqued researchers' interest. They suspected his recovery might have to do with the large number of mutations in his tumors. Now, a small clinical trial suggests that even cancer patients with types of tumors that were thought to be impervious to the new drugs could benefit if those malignancies have the right error-riddled DNA signature, a result that could help 3% to 4% of cancer patients.

In this case, developed for an introductory genetics class, students meet a woman whose family has a history of colon cancer. Students create a pedigree based on information from the case and discuss what it means to be genetically predisposed to cancer. Using bioinformatics tools from the NCBI database, students identify and examine the mutation in the woman's APC gene that results in genetic predisposition to colon cancer. Finally, they investigate the biological function of the APC protein to understand why this mutation contributes to the development of cancer and determine whether APC is a proto-oncogene, tumor suppressor gene, or genome stability gene.

Most colon cancers may be caused by infections with bacteria that are normally found in cows. For decades we have known that Streptococcus gallolyticus gallolyticus (SGG) is sometimes found in colon tumours, but now the microbes have been found to directly cause tumour growth in mice.

WEDNESDAY, April 22, 2015 (HealthDay News) -- In a step toward personalized vaccines against cancer, scientists report they have developed an immune-system therapy that knocks out several types of aggressive tumors in mice. German researchers said the findings, reported April 22 in the journal Nature, could lead to a "blueprint" for developing tailored vaccines for a range of cancers. Such vaccines would be designed for individual patients, based on the specific genetic mutations in their tumors.